X

420 with CNW — Medical Marijuana Could Expand as Feds Reschedule the Drug

A recent federal decision to reclassify medical cannabis is reshaping the outlook for licensed operators, prompting renewed attention from businesses and regulators across the country. 

The change, introduced under an order signed by Acting Attorney General Todd Blanche, moves state-approved medical cannabis to Schedule III of the CSA. That adjustment carries significant financial implications, particularly when it comes to taxation. 

Beginning in the first quarter of 2026, companies operating in the medical marijuana space will be allowed to deduct ordinary business expenses. This marks a sharp departure from previous restrictions that fell under Section 280E of the Internal Revenue Code, which has long prevented cannabis businesses from claiming such deductions. 

According to data from analytics firm Headset, the average dispensary could save around $268,000 annually under the new classification. For many businesses that have struggled to remain profitable, those savings could shift the balance, turning losses into gains. 

Recreational marijuana operators, however, remain subject to those rules for now, creating a split in how the industry is taxed. These operators are awaiting the outcome of a fast-tracked administrative review scheduled to begin June 29 and wrap up by mid-July. 

The process will determine whether they might also benefit from relief tied to Section 280E. Until then, operators and regulators are weighing their options. 

Some states are already moving ahead. In California, officials have introduced a simplified system that allows cannabis businesses to modify their license type without waiting for renewal. The Department of Cannabis Control said the change is intended to speed up approvals and reduce administrative hurdles. Businesses can now shift to a medical designation or add one alongside an existing adult-use license with fewer requirements. 

The policy shift comes as California’s once-dominant medical marijuana market has sharply declined. Sales that exceeded $2.5 billion in 2017 dropped to below $185 million by 2025. Industry observers point to high taxes, registration costs, and limited product access as factors that have driven patients elsewhere. Many have either turned to unregulated sellers or opted to purchase through adult-use channels despite having medical needs. 

The new federal classification may encourage businesses to refocus on serving medical patients, given the financial advantages now tied to that segment. It could also prompt regulators to expand access to medical licenses, particularly in states where those permits are currently concentrated among large, well-funded operators. 

In New Jersey, where recreational sales launched in 2022 through existing medical providers, regulators may consider allowing more businesses to enter the medical market. Industry consultants say discussions are already underway, though officials are still evaluating how best to respond to the evolving federal framework. 

Other states may take broader approaches. Some could consider redefining their entire cannabis market as medical in order to extend tax benefits to all licensed operators. Washington, D.C. offers a notable example. Although voters approved recreational marijuana in 2014, federal restrictions have prevented the city from establishing a traditional retail system for recreational sales. 

As a workaround, leaders created a system that allows adults over 21 to register as medical patients without a physician’s recommendation, enabling them to purchase cannabis legally through licensed dispensaries. 

The model could gain traction elsewhere if states look for ways to align with federal policy while supporting local businesses. 

Meanwhile, debate continues at the national level. Critics, including some lawmakers, argue that more research is needed on the health effects of cannabis before further regulatory changes are made. 

The evolving regulatory climate at the federal level is going to be closely watched by medical cannabis firms like Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF). 

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of an article each business day at 4:20 p.m. Eastern – a tribute to the time synonymous with cannabis culture. The concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

Chris@CNW:
Related Post